CRISPR / Gene Editing News

2026-06-19

Gene Editing Weekly — June 12–19, 2026

The week's lead story is the full Phase 3 HAELO readout for Intellia's lonvo-z — 87% HAE attack reduction, 62% attack-free at six months in 80 patients, no serious adverse events, simultaneous NEJM publication — the first in vivo CRISPR therapy to complete Phase 3. On June 18, Beam Therapeutics received FDA IND clearance for BEAM-304 (PKU base editing) and Prime Medicine received New Zealand's first-ever clinical authorization for in vivo prime editing (PM577a, Wilson disease), both citing FDA's June 2 platform-knowledge guidance. UniQure's AMT-130 FDA reversal marks the third documented CBER flexibility case. Two SCD gene editing papers (risto-cel + reni-cel) appeared in NEJM. Research highlights include the Doudna lab's 49% in vivo liver prime editing efficiency (Nature Nanotechnology) and LEAPER 2.0's 1.5-year DMD NHP durability and first-in-human data (Cell). The EU Parliament passed a gene-edited crops fast-track law.

CRISPR / Gene Editing News

Gene editing weekly — August 29–September 4, 2026: One-year editing, $400 million runway, and the cost of delivery

Gene Editing Weekly — August 22–28, 2026: PBGENE-DMD enters the clinic as prime assembly stretches the payload envelope

Gene Editing Weekly — August 14–21, 2026: FDA's CGT guidance, Genglycos, and the editing quality-control stack

Gene Editing Weekly — August 7–14, 2026: a clinical edge case, safer editing tools, and Sangamo's asset sale

Gene Editing Weekly — July 24–31, 2026: DMD base-editing follow-up, split editors, and personalized therapies

Gene Editing Weekly — July 17-24, 2026: a new clinical entry point, large-DNA insertion, and a governance failure

Gene Editing Weekly - July 10-17, 2026: ex vivo consistency, precision platforms, and bespoke trials

Gene Editing Weekly - Jun 26-Jul 3

Gene Editing Weekly — June 19–26, 2026

Gene Editing Weekly — June 12–19, 2026

Gene Editing Weekly — June 5–12, 2026

Gene Editing Weekly — May 29–June 5, 2026